Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

One-Stop In Vivo CAR Safety Assessment Services

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides an In Vivo CAR Safety Assessment Service designed to support safer and more predictable cell therapy development. This service addresses key translational challenges such as uncertain on-target/off-tumor toxicity, cytokine release risks, limitations of predictive animal models, and difficulties in evaluating biodistribution and long-term persistence of CAR-based therapeutics. By integrating preclinical in vivo modeling, multi-organ analysis, and quantitative pharmacology approaches, Creative Biolabs enables comprehensive safety evaluation of CAR-T and other engineered immune cell therapies.

Introduction

In vivo CAR safety assessment is a critical component in the development of CAR-T and CAR-NK therapies, ensuring therapeutic efficacy while minimizing systemic toxicity. Current research highlights key safety concerns such as cytokine release, neurotoxicity, and off-tumor effects, emphasizing the importance of comprehensive animal model evaluation. Integrated in vivo assessment strategies have become essential for supporting translational success and regulatory progression of engineered immune cell therapies.

Fig.1 In vitro models of CAR-T cells. (OA Literature) Fig.1 In vitro reconstruction of CAR-T cell systems.¹

Our Service

Our service provides comprehensive in vivo evaluation of CAR-based therapeutics to support preclinical development and IND-enabling studies. We deliver systematic safety profiling, including toxicity monitoring, biodistribution mapping, persistence tracking, and immune activation assessment across relevant animal models. Clients receive structured data packages that support decision-making for construct optimization and clinical translation.

We provide critical safety evaluations for CAR constructs, specializing in in vivo safety risk profiling, multi-organ distribution, and cell persistence evaluation. The platform also analyzes immune activation and cytokine responses while conducting thorough histopathological assessments to detect potential tissue toxicity. Aligned with regulatory expectations, this comprehensive testing suite ensures robust study design support to accelerate translational research and safeguard development timelines.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Platform of One-stop In Vivo CAR Safety Assessment. (Creative Biolabs Original)

Our in vivo platform evaluates human CAR cell safety and efficacy through humanized mouse models that replicate true human immune dynamics. By utilizing custom transgenic models expressing human target antigens, we systematically screen for on-target/off-tumor toxicities across normal tissues.

Our Workflow

To launch the project, clients need to provide complete CAR construct design information covering target antigen and signaling domains, engineered immune cells or viral/non-viral delivery systems, alongside defined therapeutic indications and clear experimental research objectives for our analysis.

Workflow of One-stop In Vivo CAR Safety Assessment. (Creative Biolabs Original)

You will receive a full integrated in vivo safety assessment report, biodistribution and cell persistence data covering various organs, as well as dedicated analytical reports on cytokine release and immune-related toxicities for your research evaluation.

Specialty Services

Non-Clinical Biodistribution & Targeting Evaluation Services for In Vivo CAR

Employing ultra-sensitive tissue tracking, this specialized service maps the systemic distribution and precise on-target trafficking of in vivo CAR vectors, delivering essential safety and tissue-specificity data required to accelerate preclinical pipelines toward successful regulatory filings.

Learn More →

Vector Integration Site Analysis (ISA) & Early Insertional Mutagenesis Screening Services for In Vivo CAR

To safeguard genomic integrity, our platform performs high-throughput sequencing to identify precise vector insertion landscapes and detect early oncogenic mutations, providing developers with critical safety profiling to mitigate genotoxicity risks before clinical trials begin.

Learn More →

Replication Competence & CMC Quality Control Compliance Validation Services for In Vivo CAR

Engineered for absolute regulatory compliance, this comprehensive assay suite rigorously tests for replication-competent viruses while validating CMC quality metrics, ensuring your in vivo CAR therapies meet strict global safety benchmarks and manufacturing standards.

Learn More →

Benefits

Customizable In Vivo Study Designs: Tailored animal model selection, dosing regimens, and endpoint assay configurations explicitly aligned with your therapeutic target and unique project scope.
Advanced Human Reconstitution Platforms: Highly standardized humanized mouse models ensuring stable engraftment and high-level human immune cell functional maturity.
Real-Time Longitudinal Tracking Capabilities: State-of-the-art non-invasive bioimaging paired with high-sensitivity genomic assays to map cell kinetics without premature animal termination.
Strict Quality Control & Regulatory Alignment: Study protocols executed under rigorous quality oversight, ensuring data packages meet the technical documentation stringency required.

FAQs

Q: How to distinguish on-target and off-target toxicities on the platform?

A: It combines tissue-specific antigen profiling, human antigen-expressing transgenic models and multi-organ histopathology. CAR-induced damage to antigen-positive healthy tissues means on-target/off-tumor toxicity, while damage to antigen-negative tissues indicates off-target cross-reactivity.

Q: Can the workflow adapt to CAR-NK, CAR-Macrophage and other CAR therapies?

A: Yes. The optimized safety assessment protocols are compatible with various immune effector cells. All imaging, kinetic profiling and cytokine monitoring assays can be adapted to detect unique expansion, persistence and activation features of CAR-NK, CAR-M and other CAR therapies.

Q: What measures ensure the validity of CRS modeling?

A: Standardized humanized mouse cohorts with verified human cell reconstitution are used to reduce model variability. Intensive blood sampling is conducted post-cell injection to capture transient cytokine spikes and ensure accurate CRS modeling.

Partner with Us

Creative Biolabs offers an end-to-end, translationally robust solution for One-stop In Vivo CAR Safety Assessment. By bridging the gap between innovative cell engineering and stringent regulatory demands, our platform provides the humanized models, advanced biodistribution tracking, and sensitive toxicity profiling required to progress your therapeutic candidates confidently into clinical trials. Our specialized scientific team is fully equipped to de-risk your cell therapy pipeline through customized, legally unencumbered testing methodologies. Ready to design your customized study or need a detailed quotation based on your target profile? Please reach out to our team of specialists through our online portal.

Reference

Sheng, Michael K, and William J Murphy. "Determinants of Chimeric Antigen Receptor (CAR) T Cell Success: In Vitro and In Vivo Preclinical Assessment." Cancers vol. 18,9 1412. 29 Apr. 2026. Distributed under Open Access LicenseCC BY 4.0, without modification. https://doi.org/10.3390/cancers18091412

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.